KRAS and neoplasm: As KC mice contain WT p53, we tested iASPP’s ability to suppress PC tumorigenesis independently of p53 in KPC mice which have concurrent heterozygous mutations of the KRAS and p53 that accelerate tumour onset and metastasis [26].